Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Healios K.K.

HLOSFPNK
Healthcare
Biotechnology
$2.10
$0.00(0.00%)
U.S. Market opens in 9h 44m

Healios K.K. Fundamental Analysis

Healios K.K. (HLOSF) shows moderate financial fundamentals with a PE ratio of -15.18, profit margin of -21.17%, and ROE of -79.71%. The company generates $0.1B in annual revenue with moderate year-over-year growth of 3.63%.

Key Strengths

Cash Position2651.00%
PEG Ratio-0.00
Current Ratio2.00

Areas of Concern

ROE-79.71%
Operating Margin-32.74%
We analyze HLOSF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -1689.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-1689.5/100

We analyze HLOSF's fundamental strength across five key dimensions:

Efficiency Score

Weak

HLOSF struggles to generate sufficient returns from assets.

ROA > 10%
-12.94%

Valuation Score

Excellent

HLOSF trades at attractive valuation levels.

PE < 25
-15.18
PEG Ratio < 2
-0.00

Growth Score

Moderate

HLOSF shows steady but slowing expansion.

Revenue Growth > 5%
3.63%
EPS Growth > 10%
14.85%

Financial Health Score

Excellent

HLOSF maintains a strong and stable balance sheet.

Debt/Equity < 1
0.62
Current Ratio > 1
2.00

Profitability Score

Weak

HLOSF struggles to sustain strong margins.

ROE > 15%
-7971.18%
Net Margin ≥ 15%
-21.17%
Positive Free Cash Flow
No

Key Financial Metrics

Is HLOSF Expensive or Cheap?

P/E Ratio

HLOSF trades at -15.18 times earnings. This suggests potential undervaluation.

-15.18

PEG Ratio

When adjusting for growth, HLOSF's PEG of -0.00 indicates potential undervaluation.

-0.00

Price to Book

The market values Healios K.K. at 6.85 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

6.85

EV/EBITDA

Enterprise value stands at -23.46 times EBITDA. This is generally considered low.

-23.46

How Well Does HLOSF Make Money?

Net Profit Margin

For every $100 in sales, Healios K.K. keeps $-21.17 as profit after all expenses.

-21.17%

Operating Margin

Core operations generate -32.74 in profit for every $100 in revenue, before interest and taxes.

-32.74%

ROE

Management delivers $-79.71 in profit for every $100 of shareholder equity.

-79.71%

ROA

Healios K.K. generates $-12.94 in profit for every $100 in assets, demonstrating efficient asset deployment.

-12.94%

Following the Money - Real Cash Generation

Operating Cash Flow

Healios K.K. generates limited operating cash flow of $-3.60B, signaling weaker underlying cash strength.

$-3.60B

Free Cash Flow

Healios K.K. generates weak or negative free cash flow of $-3.79B, restricting financial flexibility.

$-3.79B

FCF Per Share

Each share generates $-32.77 in free cash annually.

$-32.77

FCF Yield

HLOSF converts -8.80% of its market value into free cash.

-8.80%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-15.18

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

6.85

vs 25 benchmark

P/S Ratio

Price to sales ratio

364.41

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.62

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.00

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.80

vs 25 benchmark

ROA

Return on assets percentage

-0.13

vs 25 benchmark

ROCE

Return on capital employed

-0.25

vs 25 benchmark

How HLOSF Stacks Against Its Sector Peers

MetricHLOSF ValueSector AveragePerformance
P/E Ratio-15.1829.45 Better (Cheaper)
ROE-79.71%779.00% Weak
Net Margin-2117.36%-24936.00% (disorted) Weak
Debt/Equity0.620.26 Weak (High Leverage)
Current Ratio2.004.65 Neutral
ROA-12.94%-19344.00% (disorted) Weak

HLOSF outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Healios K.K.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

256.56%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

45.57%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

79.28%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ